Insider Transactions in Q2 2025 at Ocular Therapeutix, Inc (OCUL)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2025
|
Merilee Raines Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+22.98%
|
-
|
|
Jun 11
2025
|
Seung Suh Hong Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+22.98%
|
-
|
|
Jun 11
2025
|
Adrienne L Graves Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+21.88%
|
-
|
|
Jun 11
2025
|
Charles M Warden Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+13.94%
|
-
|
|
Jun 11
2025
|
Leslie J. Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+21.4%
|
-
|
|
Jun 11
2025
|
Richard L Md Lindstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+8.91%
|
-
|
|
Jun 02
2025
|
Nadia Waheed Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,861
-6.28%
|
$110,888
$8.05 P/Share
|
|
May 23
2025
|
Peter Kaiser Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,974
-1.42%
|
$20,818
$7.17 P/Share
|
|
May 23
2025
|
Sanjay Nayak Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,862
-0.66%
|
$13,034
$7.17 P/Share
|
|
May 23
2025
|
Pravin Dugel Director |
SELL
Open market or private sale
|
Direct |
21,219
-0.6%
|
$148,533
$7.18 P/Share
|
|
May 23
2025
|
Jeffrey S. Heier Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,024
-1.14%
|
$21,168
$7.18 P/Share
|
|
May 08
2025
|
Richard L Md Lindstrom Director |
BUY
Open market or private purchase
|
Direct |
10,000
+5.47%
|
$60,000
$6.96 P/Share
|